Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Sell

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

Glaukos Corporation (GKOS)

Surgical & Medical Instruments & Apparatus

https://www.glaukos.com

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

229 AVENIDA FABRICANTE
SAN CLEMENTE, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/25/2015

Market Cap

7,042,456,080

Shares Outstanding

48,800,000

Weighted SO

48,799,581

Total Employees

N/A

Upcoming Earnings

07/31/2024

Similar Tickers

KIDS --.--%

CNMD --.--%

LIVN --.--%

FNA --.--%

OFIX --.--%

NUVA --.--%

HSKA --.--%

BRKR --.--%

NVRO --.--%

Beta

1.0610

Last Div

0.0000

Range

59.22-128.17

Chg

3.0000

Avg Vol

540324

Mkt Cap

7042456080

Exch

NYSE

Country

US

Phone

949 367 9600

DCF Diff

150.0754

DCF

-24.9154

Div Yield

0.0000

P/S

20.6085

EV Multiple

-81.4245

P/FV

9.7715

Div Yield %

0.0000

P/E

-40.9798

PEG

-4.9539

Payout

0.0000

Current Ratio

5.4761

Quick Ratio

4.6702

Cash Ratio

0.9713

DSO

54.7054

DIO

257.0185

Op Cycle

311.7239

DPO

52.6051

CCC

259.1189

Gross Margin

0.7653

Op Margin

-0.3554

Pretax Margin

-0.4618

Net Margin

-0.4641

Eff Tax Rate

-0.0051

ROA

-0.1725

ROE

-0.3087

ROCE

-0.1429

NI/EBT

1.0051

EBT/EBIT

1.2994

EBIT/Rev

-0.3554

Debt Ratio

0.0616

D/E

0.0852

LT Debt/Cap

0.0785

Total Debt/Cap

0.0785

Int Coverage

-17.5470

CF/Debt

-1.2537

Equity Multi

1.3826

Rec Turnover

6.6721

Pay Turnover

6.9385

Inv Turnover

1.4201

FA Turnover

2.0145

Asset Turnover

0.3716

OCF/Share

-1.4014

FCF/Share

-1.6122

Cash/Share

5.1595

OCF/Sales

-0.2080

FCF/OCF

1.1504

CF Coverage

-1.2537

ST Coverage

0.0000

CapEx Coverage

-6.6478

Div&CapEx Cov

-6.6478

P/BV

9.7715

P/B

9.7715

P/S

20.6085

P/E

-40.9798

P/FCF

-86.1326

P/OCF

-91.4514

P/CF

-91.4514

PEG

-4.9539

P/S

20.6085

EV Multiple

-81.4245

P/FV

9.7715

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 21, 11:48 Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst Benzinga Dec 21, 07:36 Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday Benzinga Dec 15, 13:49 iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst Benzinga Dec 15, 13:49 iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst Benzinga Nov 28, 09:00 Analyst Ratings for Glaukos Zacks Investment Research Nov 01, 19:00 Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Zacks Investment Research Nov 01, 19:00 Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Zacks Investment Research Nov 01, 19:00 Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Revenue Product Segmentation